Oppenheimer Reiterates Outperform on Amgen, Maintains $280 Price Target
Portfolio Pulse from richadhand@benzinga.com
Oppenheimer analyst Jay Olson has reiterated an 'Outperform' rating on Amgen (NASDAQ:AMGN) and maintained a price target of $280.
July 25, 2023 | 12:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer analyst has reiterated an 'Outperform' rating on Amgen and maintained a price target of $280.
The reiteration of an 'Outperform' rating by a reputable analyst like Jay Olson from Oppenheimer is a positive signal for Amgen. The maintained price target of $280 also indicates confidence in the company's performance. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100